AIT reports Phase II data for lung infection candidate

AIT Therapeutics Inc. (Pink:AITB) reported data from nine patients with non-tuberculosis Mycobacterial (NTM) infections in the Phase II NO-NTM Abscessus trial showing that AIT-NTM for 21 days led to a mean reduction in Mycobacterium abscessus load from baseline to day 81 of 65%. The company also said improvements in 6-minute walk test (6MWT) distance were maintained at day 81.

The open-label, Israeli trial enrolled patients who were refractory to standard of care (SOC) for Mycobacterium abscessus complex (MABSC) of the lungs and had underlying cystic fibrosis to receive AIT-NTM given five times per day for 14 days and then three times per day for a subsequent seven days. The primary endpoint of the trial is safety. Secondary endpoints include 6MWT distance and Mycobacterium abscessus load in sputum...